Showing results (1851-1860 of 5,702) with videos related to

Sort By:
Pageof 571
The Oncologist|April 7, 2019
Prediction of Bone Metastasis in Inflammatory Breast Cancer Using a Markov Chain ModelTakeo Fujii, Jeremy Mason, Angela Chen, et al.
The Oncologist|April 3, 2019
Computed Tomography-Based Radiomics Signature: A Potential Indicator of Epidermal Growth Factor Receptor Mutation in Pulmonary Adenocarcinoma Appearing as a Subsolid NoduleXinguan Yang, Xiao Dong, Jiao Wang, et al.
The Oncologist|March 23, 2019
Managing Pulmonary Toxicities Associated with Immunotherapy: A Case DiscussionVanessa A Reed, Naiyer Rizvi
The Oncologist|March 21, 2019
Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE)Naoko Chayahara, Toru Mukohara, Motoko Tachihara, et al.
The Oncologist|February 25, 2014
Sorafenib in metastatic thyroid cancer: a systematic reviewLigy Thomas, Stephen Y Lai, Wenli Dong, et al.
The Oncologist|February 25, 2014
New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencingJeffrey S Ross, Kai Wang, Laurie Gay, et al.
The Oncologist|April 15, 2017
Association Study Confirmed Three Breast Cancer-Specific Molecular Subtype-Associated Susceptibility Loci in Chinese Han WomenYihui Xu, Mengyun Chen, Chenchen Liu, et al.
The Oncologist|April 15, 2017
A Host-Dependent Prognostic Model for Elderly Patients with Diffuse Large B-Cell LymphomaKatsuhiro Miura, Jun Konishi, Takaaki Miyake, et al.
The Oncologist|February 18, 2017
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal CancerJohanna C Bendell, Howard Hochster, Lowell L Hart, et al.
The Oncologist|June 3, 2008
EBV-associated lymphoproliferative disorders: classification and treatmentAntonino Carbone, Annunziata Gloghini, Giampietro Dotti
Pageof 571